CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer, Strengthening Financial Leadership Team Amid Strategic Growth Focus
CONMED Corporation has announced the appointment of John E. Gallagher as its new Chief Financial Officer (CFO), with the appointment set to take effect on July 15, 2026. The company also confirmed that outgoing CFO Todd Garner will continue to support CONMED in an advisory capacity through November 2, 2026, ensuring a structured leadership transition and continuity in financial oversight.
The appointment marks a significant leadership update for the global medical technology company as it continues to expand its presence in high-growth surgical and minimally invasive healthcare markets. CONMED emphasized that Gallagher’s extensive background in healthcare finance, medical technology operations, and public company leadership played a central role in his selection.
Leadership Transition and Strategic Continuity
The transition from Todd Garner to John Gallagher reflects a planned succession approach designed to maintain stability in financial operations while enabling a smooth handover of responsibilities. Garner’s continued advisory role for several months after the effective date is expected to support onboarding continuity, particularly across reporting structures, investor communications, and ongoing strategic initiatives.
Company leadership highlighted that this transition is aligned with CONMED’s broader objective of strengthening its financial leadership while maintaining momentum in its operational and strategic priorities. The medical technology sector, characterized by innovation cycles, regulatory considerations, and global supply chain complexity, often requires strong financial governance to support sustainable growth and capital allocation decisions.
By introducing Gallagher into the CFO role with an overlap period, CONMED is signaling its intent to minimize disruption while ensuring institutional knowledge is retained during the leadership shift.
Executive Perspective from CONMED Leadership
Patrick J. Beyer, President and Chief Executive Officer of CONMED, expressed strong confidence in the appointment, underscoring Gallagher’s experience across healthcare and medical technology sectors as a key advantage for the company.
He noted that Gallagher brings “deep healthcare and medical technology experience” along with a long track record of public company financial leadership. According to Beyer, Gallagher has demonstrated success in managing complex global finance organizations, executing strategic initiatives, and supporting operational decision-making in large-scale enterprises.
Beyer emphasized that these capabilities align closely with CONMED’s ongoing priorities, including operational execution, long-term value creation, and disciplined financial management. The CEO also highlighted his anticipation of working closely with Gallagher as the company continues to pursue growth and strengthen shareholder returns.
John E. Gallagher’s Professional Background
John E. Gallagher brings nearly three decades of experience in corporate finance and executive leadership roles across healthcare, industrial, and technology-driven organizations. His expertise spans multiple financial disciplines, including treasury management, investor relations, financial planning and analysis (FP&A), accounting, capital markets, and enterprise performance management.
Most recently, Gallagher served as Chief Financial Officer of Certara, Inc., a publicly traded pharmaceutical technology and services company, beginning in 2023. In this role, he was responsible for overseeing global financial operations and supporting the company’s strategic initiatives in the life sciences and drug development sectors.
Prior to Certara, Gallagher held the CFO position at Cue Health Inc. from 2021 to 2023. At Cue Health, a healthcare technology company focused on diagnostic solutions, he managed financial strategy during a period of rapid industry evolution and heightened demand for healthcare innovation.
A significant portion of Gallagher’s career was also spent at Becton, Dickinson & Co. (BD), a major global medical technology company. Over his nine-year tenure at BD, he held multiple senior leadership positions that expanded his exposure to both operational finance and corporate strategy.
He initially joined BD in 2012 as Corporate Treasurer, where he oversaw treasury operations and capital structure management. He also played a key role in broader corporate finance functions, including financial planning and analysis and accounting leadership. During his time at BD, Gallagher contributed to the financial management of several major acquisitions, serving as Controller and Chief Accounting Officer during periods of organizational transformation.
In 2018, he was promoted to Senior Vice President and CFO of BD’s Medical Segment, the company’s largest business division. In this role, he partnered closely with operational leaders to drive performance across a global portfolio of medical technologies, focusing on profitability, growth strategy, and operational efficiency.
Earlier in his career, Gallagher held finance leadership roles at General Electric Company and Ford Motor Company, where he gained experience in large-scale industrial operations, global financial systems, and corporate governance frameworks.
Academically, Gallagher earned his MBA from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh and holds a Bachelor of Science in Finance from Clemson University.
Gallagher’s Perspective on Joining CONMED
Following the announcement, John Gallagher expressed enthusiasm about joining CONMED and working with its leadership team. He highlighted the company’s positioning within high-growth surgical markets and its differentiated portfolio of medical technology solutions.
Gallagher stated that he looks forward to collaborating with CEO Patrick J. Beyer and the broader executive team to enhance operational and financial performance. He emphasized CONMED’s strong market position and its potential for continued value creation through strategic execution and disciplined financial management.
His comments reflect a focus on integrating financial strategy with operational priorities, particularly in areas such as capital allocation, margin improvement, and long-term shareholder value.
Strategic Context: Why the Appointment Matters
The CFO appointment comes at a time when medical technology companies are navigating a complex operating environment that includes evolving healthcare demand, supply chain pressures, regulatory oversight, and increased competition in minimally invasive surgical markets.
For CONMED, financial leadership is closely tied to its ability to invest in innovation while maintaining profitability and managing global operations effectively. The CFO role is therefore central not only to accounting and reporting but also to shaping strategic direction through investment decisions, mergers and acquisitions, and resource allocation.
Gallagher’s background in both healthcare-focused companies and industrial organizations provides him with exposure to diverse operating models, which may be beneficial as CONMED continues to expand its product portfolio and global footprint.
His experience at companies such as BD, Certara, and Cue Health suggests familiarity with both mature and high-growth business environments, giving him insight into balancing innovation-driven expansion with financial discipline.
Market and Industry Implications
Leadership changes at the CFO level are often closely watched by investors, particularly in publicly traded healthcare companies. The appointment may be interpreted as a signal of CONMED’s continued emphasis on financial discipline and strategic growth execution.
Given Gallagher’s background in capital markets and investor relations, his role may also influence how the company communicates financial performance and long-term strategy to shareholders. CFO transitions can sometimes impact investor sentiment, particularly when they involve executives with experience across multiple public companies in the same sector.
Additionally, CONMED’s continued focus on surgical technologies and minimally invasive solutions places it within a competitive segment of the medical device industry. Strong financial leadership is critical in supporting research and development investments, acquisitions, and global expansion strategies that define success in this sector.
As Gallagher prepares to assume the CFO role in mid-2026, the transition period will likely focus on integration, knowledge transfer, and alignment with CONMED’s ongoing strategic initiatives. With Todd Garner remaining in an advisory capacity for several months, the company is positioning itself for continuity during the leadership change.
The appointment reinforces CONMED’s emphasis on experienced leadership capable of managing complex financial structures while supporting innovation-driven growth. As the company advances its strategic priorities, the CFO role will remain central in balancing operational execution with long-term financial performance.
In summary, the addition of John E. Gallagher to CONMED’s executive leadership team represents a significant step in the company’s ongoing evolution. His extensive experience in healthcare finance, medical technology operations, and corporate leadership is expected to support CONMED’s ambitions as it continues to strengthen its position in global surgical markets and deliver sustained value to shareholders.
Source link: https://www.businesswire.com/
